You are here: Industry Insights > Tecentriq

News List

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer worldpharmanews
December 10, 2018
Roche announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq®
Roche's marketing application for Tecentriq in small cell lung cancer gets FDA priority review firstwordpharma
December 05, 2018
Roche said Wednesday that the FDA granted priority review to a marketing application seeking approval of Tecentriq (atezolizumab), in combination with chemotherapy, for the initial treatment of people with extensive-stage small cell lung cancer (SCLC). Th
Roche's marketing application for Tecentriq in small cell lung cancer gets FDA priority review firstwordpharma
December 05, 2018
Roche said Wednesday that the FDA granted priority review to a marketing application seeking approval of Tecentriq (atezolizumab), in combination with chemotherapy, for the initial treatment of people with extensive-stage small cell lung cancer (SCLC). Th
Roche pulls EU application for Tecentriq in kidney cancer biopharmadive
November 22, 2018
Roche has withdrawn an application to the European Medicines Agency that sought an expanded approval for its immunotherapy Tecentriq in advanced kidney cancer, concluding in a letter to the regulator data were insufficient to support a label extension.
FDA grants priority review to Roche's filing for Tecentriq in triple-negative breast cancer firstwordpharma
November 14, 2018
Roche said Tuesday that the FDA granted priority review to a filing seeking approval of Tecentriq (atezolizumab) plus chemotherapy for the first-line treatment of unresectable
Is Roche's latest Tecentriq win really a win for Merck's Keytruda? fiercepharma
July 27, 2018
With new lung cancer data, Roche touted another win Thursday for red-hot immuno-oncology drug Tecentriq. But the way some analysts see things, it may actually be a win for archrival Keytruda.
Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough fiercepharma
July 19, 2018
Roche’s Tecentriq is on a much-needed hot streak.
Roche’s Tecentriq/Cotellic study fails in colorectal cancer trial pharmatimes
July 09, 2018
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
First-line use of Roche’s Tecentriq given priority review pharmatimes
July 09, 2018
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
Roche's Tecentriq combo gives strong Phase 3 showing in triple negative breast cancer pharmafile
July 06, 2018
Roche has unveiled new Phase 3 data on its immunotherapy drug Tecentriq (atezolizumab) in combination with chemotherapy (Celgene’s Abraxane) as a first-line treatment

Previous page 1 2 3 4 5 6 7 Next page